NFKB1 and prostate neoplasm: Therefore, also in prostate tumors the biochemical intermediates involved in NF-κB activation and augmented IL-6/CCL5 gene expression might represent adequate therapeutic targets aiming at interfering with one or more of the MAPKs activation pathway(s), thereby counteracting their effects on tumor cell proliferation and migration